1 / 31

CHAMP Delirium Part 2: Evaluation & Management

CHAMP Delirium Part 2: Evaluation & Management. Andrea Bial, M.D. University of Chicago. Goals. Develop a plan for teaching a Systematic Approach to the Evaluation of hospitalized older patient with delirium.

aldis
Télécharger la présentation

CHAMP Delirium Part 2: Evaluation & Management

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. CHAMPDelirium Part 2:Evaluation & Management Andrea Bial, M.D. University of Chicago

  2. Goals • Develop a plan for teaching a Systematic Approach to the Evaluation of hospitalized older patient with delirium. • Develop a plan for teaching an appropriate Treatment Plan for the hospitalized older patient with delirium

  3. Overnight Events: Morning Rounds at the Bedside • 75yo W admit 2d ago w/ COPD, bronchitis • Intern reports: o/n she pulled out her IV, thought she was at home • X-cover ordered Prosom 1mg & po abx

  4. Overnight, cont’d • Currently, pt w/o c/o. Doesn’t recall events of previous night. • PE: sleepy, arouseable 37.6 148/62 88 20 93%2L Lungs w/ faint wheeze bilat Rest w/o change Labs WBC 13.2, diff P; H/H stable Na 133, BUN 26, Cr 1.2

  5. Overnight, cont’d • A/P #1) COPD—cont nebs, steroids, po abx #2) HTN—stable on meds #3) Confusion—add risperdal 1mg QHS prn #4) Disp—await PT/OT

  6. Systematic Approach to the Evaluation of Delirium • No one “gold standard” approach • Multiple Mnemonics (e.g., Delirium) & algorithms • Need individualized, systematic approach to avoid missing potential causes • Few studies exist specifically looking at causes

  7. Evaluation of Delirium: Causes • Francis (1990) • Large teaching hospital • General medicine patients (n=229) • Delirium developed in 22% (n=50) • Determined cause(s) as: definite, probable, or possible • 18 (36%) w/ one definite cause (Drug toxicity, then infection=fluid/lyte imbalance) • 10 (20%) w/ one probable cause • 22 (44%) w/ >1 cause; 62 possible etiologies (2.8/pt)

  8. Evaluation: Dementia Teaching Points • Hx of dementia? • Hx of sundowning? • Agitated dementia ≠ delirium 4. Importance of considering dx: DEMENTIA DELIRIUM

  9. Evaluation: Physical Exam • Head to toe: • Vitals (temp, HR, RR, BP, pulse ox, pain) • Head (CVA, bleed, meningitis, sz, blind, deaf) • Lung (pneumonia, PE, CHF) • Chest (ischemia, CHF, arrhythmia) • Abd (ischemia, impaction, bleed) • GU (UTI, retention) • Extrem (pain, volume status, CVA) • Skin (pressure ulcer, volume status)

  10. Evaluation: Head CT? • No evidence to support routine ordering • Order if: • new focal finding(s) on exam • head trauma • suspicion of encephalitis • no other identifiable causes found

  11. Evaluation: Medication Review • Too little (alcohol or other drug w/d) • Francis (1990) 1/50pts (2%) • Lawlor (2000) 4/71pts (6%) • Too much • narcotics, neuroleptics, anticholinergics, antiemetics Francis 1990, Schor 1992, Lawlor 2000

  12. Evaluation: Medication List • Antibiotics (aminogly, PCN, ceph, sulfa) • Benadryl • Benzodiazepines (triazolam, alprazolam, diazepam) • Digoxin • GI (Reglan, Bentyl) • Lithium • Narcotics • Neuroleptics • Steroids • NSAIDs (Indocin) • H2 Blockers (Cimetidine,…) • Parkinsons drugs (Levodopa, Benztropine, Amantadine) • Tricyclics

  13. Evaluation: Medication List • Antibiotics (aminogly, PCN, ceph, sulfa) • Benadryl • Benzodiazepines (triazolam, alprazolam, diazepam) • Digoxin • GI (Reglan, Bentyl) • Lithium • Narcotics • Neuroleptics • Steroids • NSAIDs (Indocin) • H2 Blockers (Cimetidine,…) • Parkinsons drugs (Levodopa, Benztropine, Amantadine) • Tricyclics

  14. Evaluation: Medications, cont’d Anticholinergic properties frequently overlooked: Elavil(amitriptyline)Flexeril(cyclobenzaprine) Cogentin(benztropine)Atarax/Vistaril(hydroxyzine) Bentyl(dicyclomine)Welbutrin/Zyban(bupropion) Ditropan(oxybutynin)Antivert(meclizine) Detrol(tolterodine)Ipratropium(atrovent) Benadryl (diphenhydramine)Phenergan(promethazine) Zyprexa(olanzapine) Atropine Levsin(hyoscyamine)Quinidine

  15. Evaluation: Additional tests • Labs • CBC, lytes, liver, renal • Consider TSH, B12, cortisol, ammonia, abg • Drug levels (digoxin, etc) • Urine tox, UA • CXR • EKG • EEG

  16. Evaluation: EEG • Since 1950’s, recommendations for EEGs • Usually: generalized slowing • Sensitivity 75%

  17. Management: Non-Pharmacologic • Cognition: orientation board (carry pen!) & open drapes during day • Sleep: minimize deprivation (no 2am labs, no o/n BS/vitals if able, give meds when awake) • Mobility: OOBchair asap, PT/OT, no foley/restraints • Vision: glasses • HOH: get aids; adapt environment; stethoscope trick • Dehydration: po fluids; observe at mealtime; avoid “Boost at nightstand” • Observation: Involve family (rotate members) or get sitter; move pt to room close to RN station

  18. Management: Non-Pharmacologic Restraint Use • Avoid whenever possible; use only if needed for patient or staff safety • Increase risk of falls, injury, agitation & worsened delirium • Use only in emergency, for as short a duration as possible with frequent re-evaluations, and d/c asap • Absolutely no “sheeting”

  19. Management: Pharmacologic • Few RCT of treating delirium in hosp pt • Extrapolation from other populations studied (AIDS, NHs, outpatient AD, …) • Mainstay of tx: antipsychotics • NOT FDA-approved for use in delirium • Need to choose type and dose carefully • Black box warning of increased mortality w/ use of antipsychotics in older pts (infectious and cardiac causes of death) • See Table in handout

  20. Management: Pharmacologic Antipsychotics Typical: Haloperidol Advantages:min sedating less ↓BP Disadvantages: ↑ sz risk more EPS side effects ↑ QT ↑ risk of Torsades Dose: 0.25-0.5mg po, IM, IV * *risk of QTc prolongation w/ IV APA 1999

  21. Management: Pharmacologic Antipsychotics, cont’d Atypicals: Advantages: less EPS +/- sedation Disadvantages: ↓ BP weight gain ↑ BS ↑mx (infection, CVS)

  22. Management: Pharmacologic Antipsychotics, cont’d Starting Daily Doses: Risperidone: 0.25-0.5mg PO Olanzapine: 2.5-5mg IM,PO Aripiprazole: 2-5mg PO Quetiapine: 12.5mg-25 PO bid* *some concern for QTc prolongation; better in PD pts

  23. Management: Pharmacologic Benzodiazepines Should not be used as first-line agents; may prolong or worsen delirium Used best if pt is delirious due to w/d of EtOH or benzo’s • Consider use in PD, NMS • Consider use as second-line, esp if sedation is desired Lorazepam 0.5-1mg PO, IM, IV q4-6hrs (no adjustment needed for liver or renal dz)

  24. Management: Pharmacologic Bottom Line • Try to avoid meds, but if needed: • Use haloperidol (or olanzapine) in acute settings; start low and titrate carefully according to symptoms. • Use risperidone, if needed for longer-term use (unless PD: quetiapine or lorazepam) • Use lorazepam for w/d

  25. Back to case! • 75yo W admit 2d ago w/ COPD, bronchitis • Intern reports: o/n she pulled out her IV, thought she was a home • X-cover ordered Prosom 1mg & po abx • Currently, pt w/o c/o. Doesn’t recall events of previous night. • PE: sleepy, arouseable 37.6 148/62 88 20 93%2L Lungs w/ faint wheeze bilat Rest w/o change Labs WBC 13.2, diff P; H/H stable Na 133, BUN 26, Cr 1.2 • A/P #1) COPD—cont nebs, steroids, po abx #2) HTN—stable on meds #3) Confusion—add risperdal 1mg QHS prn #3) Disp—await PT/OT

  26. Teaching Points • Ask: What do you think caused last night’s events? • Was a h/o dementia missed? (dementia/delirium relationship; role of MMSE; further family hx) • Was her PE different at the time x-cover was called? (systematic evaluation/head-to-toe) • Did we start or alter dose of any medications? (nebs, steroids, abx)

  27. Teaching Points, cont’d • Ask: Is she delirious now? • Discuss use of CAM (comfort of tool; dx of delirium in chart) • Discuss outcomes of delirium (increases: LOS, healthcare costs, mx, d/c to LTCF) • Discuss use of Prosom (and other benzo’s) in delirium

  28. Teaching Points, cont’d • Ask: Is there anything we should do today to follow-up on her confusion? • Discuss further studies that may or may not be needed (CXR? UA? Repeat Na?) • Discuss the non-pharmacologic measures that should be put into place (orient board, fluids, mobility, drapes, HS nebs & labs) • Discuss use of risperidone (and other antipsychotics) in delirium

  29. Recommended Reading • Inouye SK. Delirium in older persons. NEJM 2006;354:1157-65 • Schneider LS et al. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer’s disease. NEJM 2006;355:1525-38. • Sink KM et al. Pharmacological treatment of neuropsychiatric symptoms of dementia. JAMA 2005;293:596-608. • Breitbart W et al. Agitation and delirium at end of life. JAMA 2008;300(24)2898-2910. • Martins S. Delirium in elderly people: a review. Front Neuro 2012;3(101)1-12.

More Related